Keeping pharmaceuticals moving post - Brexit

09 August 2019

The uncertainty around Brexit has continued for longer than many expected, with concerns in all corners of the business world continuing unabated – and the pharmaceutical industry is far from the exception.

 

Earlier this year, the Royal College of Physicians called on the government to be more transparent around the issue of stockpiling medication, and the Healthcare Distributors Association has voiced similar concerns, amongst many others.

When it comes to Brexit planning, one option is to sit back and wait to see what happens. In many ways, this approach is tempting, particularly with so much still up in the air.

However, we can also look at the ‘extra time’ we have gained around Brexit as an opportunity to plan for a number of outcomes, ensuring the best chance of returning to business as usual once a deal is agreed and implemented.

Like so many Brexit concerns, the issue around access to and availability of pharmaceuticals is primarily a logistics one. How do we get our products transported legally, safely and on time to ensure business continuity?

The key is to take a scenario-based approach to planning for any potential supply chain disruption, which will deliver a pathway for distribution no matter what Brexit agreement lies ahead.

To continue reading the article written by GEFCO UK Customs and Tax Manager, Tim Harding, please click here.

 

Share